Health TrialsbyHealthPanel

Antihistamines, Amantadine and Evolution of COVID-19

ConditionCOVID-19
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorConsorci Sanitari de Terrassa

About this trial

The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Population assigned to the Public and free Access Terrassa Health Consortium

Trial design

Design model

Case-control

Time perspective

Retrospective

Treatments tested in this trial

  • Antihistamine

    Drug

    Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines

  • Amantadine

    Drug

    Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine

Treatment groups

140,660 Participants
are divided into 2 treatment groups
Group A: Patients with chronic treatment with antihistamines or amantadine2 interventions
Group B: Other population of the THC0 interventions

Trial outcomes

Primary outcomes

1

Hospital Admissions.

Rate of Hospitalization among COVID 19 infections

Time frame
from march 2020.

Secondary outcomes

1

Survival

Survival among COVID1 hospitalized cases.

Time frame
from march 2020
2

Symptomatic infection

Patients suffering a symptomatic COVID19 infection within a determinate age group

Time frame
from march 2020
3

Postcovid syndrome

Patients developing postcovid syndrome after COVID19 infection

Time frame
from april 2020
4

Thrombosis

Patients developing thrombosis (with particular assessment of stroke, cardiac infarction, retinal vessels and pulmonary embolism)

Time frame
from april 2020

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Consorci Sanitari de Terrassa

Lead sponsor

Institut Català de la Salut

Collaborator

Source ClinicalTrials.gov
Apply now